CClinicalTrials.gg
Status unknownNCT03362645DEFYUpdated Dec 5, 2017

Diagnostic Value of the Electrocardiogram in Fabry Disease

An observational study in Fabry, sponsored by University Hospital, Caen. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-05.

Sponsored by University Hospital, Caen · Observational

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Cardiac complications occur in 78% of patients with Fabry disease and are mainly characterized by a high frequency of left ventricular hypertrophy resulting from an accumulation of GL3 in cardiomyocytes. Apart from family screening, left ventricular hypertrophy is an important factor in the diagnosis of Fabry disease. This left ventricular hypertrophy is more often concentric and homogeneous, but it can also be asymmetric and mimic the patterns seen in so-called familial hypertrophic cardiomyopathies caused by mutations in the sarcomere protein genes. Electrocardiogram has been suggested as a screening tool for Fabry disease. Analysis of the PQ interval would be of interest. An algorithm has even been proposed to differentiate Fabry disease from amyloidosis with excellent sensitivity and specificity. The only criterion of left ventricular hypertrophy used in all studies is the Sokolov-Lyon index, but this index has many limitations and does not appear to be discriminatory for Fabry disease. Other validated criteria for left ventricular hypertrophy, such as the Cornell, Lewis, Gubner index or the Romhilt-Estes point score, have never been tested in Fabry disease. The primary objective of our study is to evaluate the diagnostic value of different electrocardiographic scores of left ventricular hypertrophy in Fabry disease.

02

Conditions studied

  • Fabry

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients aged > 18 years, with genetically confirmed Fabry disease complicated by LVH.

Patients aged > 18 years, with sarcomeric hypertrophic cardiomyopathy.

Inclusion criteria

  • Patients aged > 18 years, with genetically confirmed Fabry disease complicated by LVH.
  • Patients aged > 18 years, with sarcomeric hypertrophic cardiomyopathy.

Exclusion criteria

Exclusion Criteria:

  • Patients aged \< 18 years. Sarcomeric hypertrophic cardiomyopathy for which Fabry disease has not been excluded by alpha-galactosidase A assay (in men) and genetic analysis (GLA gene mutation) in women.
04

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Fabry cardiomyopathy
  • Hypertrophic cardiomyopathy
05

What researchers measure

Primary outcomes

  1. Analysis of the PQ interval with a new algorithm

    Determine whether electrocardiographic criteria of left ventricular hypertrophy allow to distinguish between Fabry disease and sarcomeric hypertrophic cardiomyopathy

    Time frame: baseline

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT03362645
Lead sponsor
University Hospital, Caen
Responsible party
Sponsor
First posted
Dec 5, 2017
Start date
Mar 2018 (estimated)
Primary completion
Mar 2019 (estimated)
Completion
Oct 2019 (estimated)
Last update
Dec 5, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion